SlideShare a Scribd company logo
1 of 31
Leprosy
(Hansen’s Disease)
By
N.SRAVANTHI REDDY (O9DH1ROO34)
Under the supervision of
K.RAMANJANEYULU(Ph.D)
Dept of pharmaceutical
chemistry
VIPER
Contents
leprosy
Causes
Classification
Symptoms
Risks
Treatment(chemotherapy)
Dosage
Adverse effects
Global situation
R & D
References
What is Leprosy?
Chronic infectious disease.
World's oldest recorded disease ( 600B.C )
was well-recognized in the civilizations of
ancient China, Egypt, and India.
Gerhard Armauer Hansen
Every year January 27 is World Leprosy Day
CausesCauses
Mycobacterium leprae
Rod Shaped
First bacterium disease in
humans
Humans and Armadillos are
only known natural hosts
M. leprae appear red when a
Ziehl-Neelsen stain is used,helps in finding
Classification
 Tuberculoid Leprosy (TL)
 Borderline Tuberculoid Leprosy (BT)
 Borderline borderline Leprosy (BB)
 Borderline lepromatous Leprosy (BL)
 Lepromatous leprosy(LL)
BASED ON SIZE :
Paucibacillary Leprosy (PB) : skin lesions with
no bacilli(M.Leprae) seen in the skin smear
Multibacillary Leprosy (MB): skin lesions with
bacilli (M.Leprae)seen in the skin smear
Tuberculoid leprosy:
Can be either one large red patch with well-defined raised
borders or a large hypopigmented asymmetrical spot
Lesions become dry and hairless
Loss of sensation may occur at site of some lesions
Enlargement of nerves with subsequent loss of function are
common
Spontaneous resolution may occur in a few years or it may
progress to borderline or rarely lepromatous types
Borderline
tuberculoid
Similar to tuberculoid
type except that lesions
are smaller and more
numerous
Disease may stay in this
stage or convert back to
tuberculoid form, or
progress
Borderline
borderline
Numerous, red,
irregularly shaped plaques
Sensory loss is moderate
Disease may stay in this
stage, improve or worsen
Numerous lesions of all kinds, plaques, macules,
papules and nodules. Lesions looking like inverted
saucers are common
Hair growth and sensation are usually not impaired
over the lesions
Borderline lepromatous
Numerous lesions of all kinds,
plaques, macules, papules and
nodules
Early symptoms include nasal
stuffiness, discharge and
bleeding, and swelling of the
legs and ankles
Lepromatous leprosy
Left untreated, the following problems may occur:
Skin thickens over forehead (leonine facies), eyebrows and
eyelashes are lost, nose becomes misshapen or collapses,
ear lobes thicken, upper incisor teeth fall out
Eye involvement causing photophobia (light sensitivity),
glaucoma and blindness
Skin on legs thickens and forms ulcers when nodules break
down
Internal organ infection causing enlarged liver and lymph
nodes
Voice becomes hoarse
What are the symptoms?
Paucibacillary (PB) Leprosy
symptoms are:
Well defined skin lesions that are
numb
Multibacillary (MB) Leprosy
symptoms are:
– Chronically stuffy nose and many skin
lesions and nodules on both sides of the
body
• Mycobacterium leprare multiplies very slowly
• Symptoms can take as long as 20 years to appear
Who is at risk?
Mainly affects:
Skin
Eyes
The peripheral nerves
Mucosa of the upper
respiratory tract
• It can affect all ages and both sexes
Who is at risk?
A 24-year-old man
infected with leprosy
Pharmaceutical Treatment
Multiple Drug Treatment (MDT)
• Effective chemotherapeutic agents:
Dapsone (diamino diphenyl sulfone,
DDS) which was discovered in early
1940’s
Rifampicin (RFP), Clofazimine (CLF)
discovered in 1960’s
Ofloxacin (OFLX), and Minocycline
(MINO) constitute the backbone of the
multidrug therapy (MDT) regimen.
Structure of Dapsone (DDS)
http://images.google.com/imgres?imgurl=http://upload.wikimedia.org/wikipedia/commons/thumb/c/c2/Dapsone.svg/671px-
Dapsone.svg.png&imgrefurl=http://commons.wikimedia.org/wiki/Image:Dapsone.svg&h=290&w=671&sz=11&hl=en&start=13&um=1&tbnid=ihM5GO42l13LYM:&tbnh=60&tbnw=138&pre
v=/images%3Fq%3Ddapsone%26um%3D1%26hl%3Den
About Dapsone
It was dicovered by German chemists Fromm
and Wittmann in 1908
Was not utilized as a treatment until decades
later
Available in 25mg & 100 mg tablets
Rated a pregnancy risk category C by the
American Food and Drug Administration
About Rifampicin
In the U.S. Rifampicin is marketed
as:
Rifadin (Aventis)
Rifater ( in combination with
isoniazid and pyrazinamide)
(Aventis)
Rimactane (Novartis)
Rated a pregnancy risk category C
by the American Food and Drug
Administration
About Clofazimine
Brand Name: Lamprene
Generic Name: Clofazimine
Initially known as B663, was first synthesized in
1954 by Dr. Vincent Barry and his team as an
anti-tuberculosis drug
Is marketed under the trade name Lamprene®
by Novartis
Dosage
http://images.google.com/imgres?imgurl=http://upload.wikimedia.org/wikipedia/commons/thumb/7/71/MDTRegimens.jpg/400px-
MDTRegimens.jpg&imgrefurl=http://en.wikipedia.org/wiki/Leprosy&h=258&w=400&sz=24&hl=en&start=15&um=1&tbnid=wA9E8CWvT_HvoM:&tbnh=80&tbnw=124&prev=/images%3Fq%3DMultidrug%2Btherapy%2B(MDT)
%2Bregimen%26um%3D1%26hl%3Den
Dosage Cont’d......
RFP Dapsone
Adult
50-70kg
600mg/m* 100mg/d
Child
10-14 years
450mg/m* 50mg/d
Less than 10
years
300mg/m* 25mg/d
Multidrug Therapy for Paucibacillary (PB) Leprosy
PB patients treated with MDT are cured within six
months
*RFP monthly doses are given under supervision
Dosage Cont’d......
RFP Dapso
ne
CLF
Adult
50-70kg
600mg/m
*
100mg
/d
50mg/d
&300mg/m*
Child
10-14
years
450mg/m
*
50mg/
d
50mg/d
&150mg/m*
Less than
10 years
300mg/m
*
25mg/
d
50mg
twice/d
&100mg/m*
Multidrug Therapy for Multibacillary (MB) Leprosy
*RFP and CLF monthly doses are given under supervision
MB patients treated with MDT are cured within 12 months
Cost of MDT
Since 1995, WHO has supplied MDT FREE of cost to all
leprosy patients in the world.
Initially drug funds were provided by Nippon Foundation
Since 2000, donations are provided by Novartis and the
Novartis Foundation for Sustainable Development
Side Effects
Dapsone (DDS)
Rifampicin (RFP)
Clofazimine (CLF)
Occasional cutaneous
eruptions
A slight reddish coloration of
urine, sweat, and tears
Brownish Black discoloration
and dryness of skin
Cases around the World
A 20% annual decrease in new cases detected globally since 2001.
the disease has been eliminated from 108 out of 122.
A Day in the Patient’s Life
AN AFFECTIONATE HAND FOR THE NEEDY……….
http://i193.photobucket.com/albums/z96/whengzky/FR%20Joy%20pix/641c.jpg
JALANETI:
Technique related to yoga.
It is the best remedy for nasal stiffness.
Normal saline is passed through one nostril and is
collected from other , which flushes the micro
organisms.
The disease was known in Ancient Greece as elephantiasis
A common pre-modern treatment of leprosy
was chaulmoogra oil.
The oil has long been used in India as an
Ayurvedic medicine for the treatment of leprosy
and various skin conditions.
It has also been used in China and Burma, and
was introduced to the West by Frederic John , a
professor at Bengal Medical CollegeBengal Medical College.
 He tried the oil as an oral and topical agent in
two cases of leprosy and reported significant
improvements in an 1854 paper.
REFERENCES:
 Sasaki S, Takeshita F, Okuda K, Ishii N (2001). "Mycobacterium leprae and leprosy: a compendium"
. Microbiol Immunol 45 (11): 729–36. PMID 11791665.
http://www.jstage.jst.go.jp/article/mandi/45/11/729/_pdf. ^ a b c
"New Leprosy Bacterium: Scientists Use Genetic Fingerprint To Nail 'Killing Organism'".
ScienceDaily. 2008-11-28. http://www.sciencedaily.com/releases/2008/11/081124141047.htm.
Retrieved 2010-01-31. ^ a b c
Kenneth J. Ryan, C. George Ray, editors. (2004). Ryan KJ, Ray CG. ed.
Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 451–3. ISBN 0838585299. OCLC
61405904 52358530 61405904. ^ a b
"Lifting the stigma of leprosy: a new vaccine offers hope against an ancient disease". Time 119 (19):
87. May 1982. PMID 10255067.
http://www.time.com/time/magazine/article/0,9171,925377,00.html. ^ Kulkarni GS (2008).
Textbook of Orthopedics and Trauma (2 ed.). Jaypee Brothers Publishers. p. 779. ISBN 8184482426,
9788184482423. ^ "Q and A about leprosy". American Leprosy Missions.
http://www.leprosy.org/getinformed/aboutleprosy/leprosyfaq.php. Retrieved 2011-01-22.17 - PRABHAKAR, M.C.; APPA RAO, A.V.N.; KRISHNA,
D.R.; RAMANAKAR, T.V. How much noninfectious
are the
"non-infectious" lepromatous leprosy patients?
Leprosy- India, 55(3): 576-583, 1983.
ESSENTIALS OF MEDICAL PHARMACOLOGY BY K.D.TRIPATHI.
Leprosy.ppt new
Leprosy.ppt new

More Related Content

What's hot (20)

Leprosy
LeprosyLeprosy
Leprosy
 
Leprosy
LeprosyLeprosy
Leprosy
 
Psoriasis
PsoriasisPsoriasis
Psoriasis
 
Ankylosing spondylitis,Causes,symptoms,diagnosis,management
Ankylosing spondylitis,Causes,symptoms,diagnosis,managementAnkylosing spondylitis,Causes,symptoms,diagnosis,management
Ankylosing spondylitis,Causes,symptoms,diagnosis,management
 
Filariasis
Filariasis Filariasis
Filariasis
 
Scabies
ScabiesScabies
Scabies
 
Scabies
ScabiesScabies
Scabies
 
Management of Leprosy
Management of LeprosyManagement of Leprosy
Management of Leprosy
 
Leprosy
Leprosy Leprosy
Leprosy
 
Meningitis
MeningitisMeningitis
Meningitis
 
Leprosy
LeprosyLeprosy
Leprosy
 
Hansen's disease
Hansen's diseaseHansen's disease
Hansen's disease
 
Leprosy
LeprosyLeprosy
Leprosy
 
Pathophysiology of Leprosy
Pathophysiology of LeprosyPathophysiology of Leprosy
Pathophysiology of Leprosy
 
Epidemiology & prevention of tuberculosis
Epidemiology & prevention of tuberculosisEpidemiology & prevention of tuberculosis
Epidemiology & prevention of tuberculosis
 
Leprosy - Introduction and Epidemiology
Leprosy - Introduction and EpidemiologyLeprosy - Introduction and Epidemiology
Leprosy - Introduction and Epidemiology
 
My Lecture On leprosy
My Lecture On leprosyMy Lecture On leprosy
My Lecture On leprosy
 
Lymphatic filariasis
Lymphatic filariasisLymphatic filariasis
Lymphatic filariasis
 
Leprosy
LeprosyLeprosy
Leprosy
 
Japanese Encephalitis
Japanese EncephalitisJapanese Encephalitis
Japanese Encephalitis
 

Similar to Leprosy.ppt new

LEPROSY presentation pptx
LEPROSY  presentation pptxLEPROSY  presentation pptx
LEPROSY presentation pptxMUSHTAQ AHMED
 
leprosy-151210122732.pdf
leprosy-151210122732.pdfleprosy-151210122732.pdf
leprosy-151210122732.pdfOgunsina1
 
Mycobacteria .pptx
Mycobacteria .pptxMycobacteria .pptx
Mycobacteria .pptxHaider Ali
 
Mycobacterium Mycobacterium tuberculosis
Mycobacterium Mycobacterium tuberculosisMycobacterium Mycobacterium tuberculosis
Mycobacterium Mycobacterium tuberculosisKARTHIK REDDY C A
 
Naipunyam-4 Monkeypox (PPT).pptx ZOONOTIC DISEASE
Naipunyam-4 Monkeypox (PPT).pptx ZOONOTIC DISEASENaipunyam-4 Monkeypox (PPT).pptx ZOONOTIC DISEASE
Naipunyam-4 Monkeypox (PPT).pptx ZOONOTIC DISEASEdrdeepthirdy18
 
Tuberculosis chemotherapy (1) (1) (1)
Tuberculosis   chemotherapy (1) (1) (1)Tuberculosis   chemotherapy (1) (1) (1)
Tuberculosis chemotherapy (1) (1) (1)ArmanShaikh17
 
Epidemiology of some Diseases Caused by Gram +ve Bacteria
Epidemiology of some Diseases Caused by Gram +ve BacteriaEpidemiology of some Diseases Caused by Gram +ve Bacteria
Epidemiology of some Diseases Caused by Gram +ve BacteriaAj Aj
 
Common URTI diseases.pptx
Common URTI diseases.pptxCommon URTI diseases.pptx
Common URTI diseases.pptxAbdiWakjira2
 
Jón Hjaltalín Ólafsson, Roderick James Hay (eds.) - Antibiotic and Antifungal...
Jón Hjaltalín Ólafsson, Roderick James Hay (eds.) - Antibiotic and Antifungal...Jón Hjaltalín Ólafsson, Roderick James Hay (eds.) - Antibiotic and Antifungal...
Jón Hjaltalín Ólafsson, Roderick James Hay (eds.) - Antibiotic and Antifungal...GajahNauli2
 
"A Study of Clinical Profile of Leprosy in Post Leprosy Elimination Era"
"A Study of Clinical Profile of Leprosy in Post Leprosy Elimination Era""A Study of Clinical Profile of Leprosy in Post Leprosy Elimination Era"
"A Study of Clinical Profile of Leprosy in Post Leprosy Elimination Era"iosrjce
 
air borne disease by ujwal virkhare
air borne disease by ujwal virkhareair borne disease by ujwal virkhare
air borne disease by ujwal virkhareUjwalVirkhare1
 

Similar to Leprosy.ppt new (20)

LEPROSY presentation pptx
LEPROSY  presentation pptxLEPROSY  presentation pptx
LEPROSY presentation pptx
 
Leprosy
LeprosyLeprosy
Leprosy
 
Leprosy
LeprosyLeprosy
Leprosy
 
Leprosy review
Leprosy reviewLeprosy review
Leprosy review
 
leprosy-151210122732.pdf
leprosy-151210122732.pdfleprosy-151210122732.pdf
leprosy-151210122732.pdf
 
Mycobacteria .pptx
Mycobacteria .pptxMycobacteria .pptx
Mycobacteria .pptx
 
ENVIROMENTAL HAZARDS CAUSES& SOLUTION
 ENVIROMENTAL HAZARDS CAUSES& SOLUTION ENVIROMENTAL HAZARDS CAUSES& SOLUTION
ENVIROMENTAL HAZARDS CAUSES& SOLUTION
 
Mycobacterium leprae
Mycobacterium lepraeMycobacterium leprae
Mycobacterium leprae
 
Mycobacterium Mycobacterium tuberculosis
Mycobacterium Mycobacterium tuberculosisMycobacterium Mycobacterium tuberculosis
Mycobacterium Mycobacterium tuberculosis
 
Naipunyam-4 Monkeypox (PPT).pptx ZOONOTIC DISEASE
Naipunyam-4 Monkeypox (PPT).pptx ZOONOTIC DISEASENaipunyam-4 Monkeypox (PPT).pptx ZOONOTIC DISEASE
Naipunyam-4 Monkeypox (PPT).pptx ZOONOTIC DISEASE
 
Leprosy -BASICS
Leprosy -BASICSLeprosy -BASICS
Leprosy -BASICS
 
Leprosy
LeprosyLeprosy
Leprosy
 
Tuberculosis chemotherapy (1) (1) (1)
Tuberculosis   chemotherapy (1) (1) (1)Tuberculosis   chemotherapy (1) (1) (1)
Tuberculosis chemotherapy (1) (1) (1)
 
Epidemiology of some Diseases Caused by Gram +ve Bacteria
Epidemiology of some Diseases Caused by Gram +ve BacteriaEpidemiology of some Diseases Caused by Gram +ve Bacteria
Epidemiology of some Diseases Caused by Gram +ve Bacteria
 
Common URTI diseases.pptx
Common URTI diseases.pptxCommon URTI diseases.pptx
Common URTI diseases.pptx
 
Jón Hjaltalín Ólafsson, Roderick James Hay (eds.) - Antibiotic and Antifungal...
Jón Hjaltalín Ólafsson, Roderick James Hay (eds.) - Antibiotic and Antifungal...Jón Hjaltalín Ólafsson, Roderick James Hay (eds.) - Antibiotic and Antifungal...
Jón Hjaltalín Ólafsson, Roderick James Hay (eds.) - Antibiotic and Antifungal...
 
Clinical assignmnt
Clinical assignmntClinical assignmnt
Clinical assignmnt
 
"A Study of Clinical Profile of Leprosy in Post Leprosy Elimination Era"
"A Study of Clinical Profile of Leprosy in Post Leprosy Elimination Era""A Study of Clinical Profile of Leprosy in Post Leprosy Elimination Era"
"A Study of Clinical Profile of Leprosy in Post Leprosy Elimination Era"
 
air borne disease by ujwal virkhare
air borne disease by ujwal virkhareair borne disease by ujwal virkhare
air borne disease by ujwal virkhare
 
Chan final-candida
Chan final-candidaChan final-candida
Chan final-candida
 

Leprosy.ppt new

  • 1. Leprosy (Hansen’s Disease) By N.SRAVANTHI REDDY (O9DH1ROO34) Under the supervision of K.RAMANJANEYULU(Ph.D) Dept of pharmaceutical chemistry VIPER
  • 3. What is Leprosy? Chronic infectious disease. World's oldest recorded disease ( 600B.C ) was well-recognized in the civilizations of ancient China, Egypt, and India. Gerhard Armauer Hansen Every year January 27 is World Leprosy Day
  • 4. CausesCauses Mycobacterium leprae Rod Shaped First bacterium disease in humans Humans and Armadillos are only known natural hosts M. leprae appear red when a Ziehl-Neelsen stain is used,helps in finding
  • 5. Classification  Tuberculoid Leprosy (TL)  Borderline Tuberculoid Leprosy (BT)  Borderline borderline Leprosy (BB)  Borderline lepromatous Leprosy (BL)  Lepromatous leprosy(LL)
  • 6. BASED ON SIZE : Paucibacillary Leprosy (PB) : skin lesions with no bacilli(M.Leprae) seen in the skin smear Multibacillary Leprosy (MB): skin lesions with bacilli (M.Leprae)seen in the skin smear
  • 7. Tuberculoid leprosy: Can be either one large red patch with well-defined raised borders or a large hypopigmented asymmetrical spot Lesions become dry and hairless Loss of sensation may occur at site of some lesions Enlargement of nerves with subsequent loss of function are common Spontaneous resolution may occur in a few years or it may progress to borderline or rarely lepromatous types
  • 8. Borderline tuberculoid Similar to tuberculoid type except that lesions are smaller and more numerous Disease may stay in this stage or convert back to tuberculoid form, or progress Borderline borderline Numerous, red, irregularly shaped plaques Sensory loss is moderate Disease may stay in this stage, improve or worsen
  • 9. Numerous lesions of all kinds, plaques, macules, papules and nodules. Lesions looking like inverted saucers are common Hair growth and sensation are usually not impaired over the lesions Borderline lepromatous
  • 10. Numerous lesions of all kinds, plaques, macules, papules and nodules Early symptoms include nasal stuffiness, discharge and bleeding, and swelling of the legs and ankles Lepromatous leprosy
  • 11. Left untreated, the following problems may occur: Skin thickens over forehead (leonine facies), eyebrows and eyelashes are lost, nose becomes misshapen or collapses, ear lobes thicken, upper incisor teeth fall out Eye involvement causing photophobia (light sensitivity), glaucoma and blindness Skin on legs thickens and forms ulcers when nodules break down Internal organ infection causing enlarged liver and lymph nodes Voice becomes hoarse
  • 12. What are the symptoms? Paucibacillary (PB) Leprosy symptoms are: Well defined skin lesions that are numb Multibacillary (MB) Leprosy symptoms are: – Chronically stuffy nose and many skin lesions and nodules on both sides of the body • Mycobacterium leprare multiplies very slowly • Symptoms can take as long as 20 years to appear
  • 13. Who is at risk? Mainly affects: Skin Eyes The peripheral nerves Mucosa of the upper respiratory tract • It can affect all ages and both sexes
  • 14. Who is at risk? A 24-year-old man infected with leprosy
  • 15. Pharmaceutical Treatment Multiple Drug Treatment (MDT) • Effective chemotherapeutic agents: Dapsone (diamino diphenyl sulfone, DDS) which was discovered in early 1940’s Rifampicin (RFP), Clofazimine (CLF) discovered in 1960’s Ofloxacin (OFLX), and Minocycline (MINO) constitute the backbone of the multidrug therapy (MDT) regimen.
  • 16. Structure of Dapsone (DDS) http://images.google.com/imgres?imgurl=http://upload.wikimedia.org/wikipedia/commons/thumb/c/c2/Dapsone.svg/671px- Dapsone.svg.png&imgrefurl=http://commons.wikimedia.org/wiki/Image:Dapsone.svg&h=290&w=671&sz=11&hl=en&start=13&um=1&tbnid=ihM5GO42l13LYM:&tbnh=60&tbnw=138&pre v=/images%3Fq%3Ddapsone%26um%3D1%26hl%3Den
  • 17. About Dapsone It was dicovered by German chemists Fromm and Wittmann in 1908 Was not utilized as a treatment until decades later Available in 25mg & 100 mg tablets Rated a pregnancy risk category C by the American Food and Drug Administration
  • 18. About Rifampicin In the U.S. Rifampicin is marketed as: Rifadin (Aventis) Rifater ( in combination with isoniazid and pyrazinamide) (Aventis) Rimactane (Novartis) Rated a pregnancy risk category C by the American Food and Drug Administration
  • 19. About Clofazimine Brand Name: Lamprene Generic Name: Clofazimine Initially known as B663, was first synthesized in 1954 by Dr. Vincent Barry and his team as an anti-tuberculosis drug Is marketed under the trade name Lamprene® by Novartis
  • 21. Dosage Cont’d...... RFP Dapsone Adult 50-70kg 600mg/m* 100mg/d Child 10-14 years 450mg/m* 50mg/d Less than 10 years 300mg/m* 25mg/d Multidrug Therapy for Paucibacillary (PB) Leprosy PB patients treated with MDT are cured within six months *RFP monthly doses are given under supervision
  • 22. Dosage Cont’d...... RFP Dapso ne CLF Adult 50-70kg 600mg/m * 100mg /d 50mg/d &300mg/m* Child 10-14 years 450mg/m * 50mg/ d 50mg/d &150mg/m* Less than 10 years 300mg/m * 25mg/ d 50mg twice/d &100mg/m* Multidrug Therapy for Multibacillary (MB) Leprosy *RFP and CLF monthly doses are given under supervision MB patients treated with MDT are cured within 12 months
  • 23. Cost of MDT Since 1995, WHO has supplied MDT FREE of cost to all leprosy patients in the world. Initially drug funds were provided by Nippon Foundation Since 2000, donations are provided by Novartis and the Novartis Foundation for Sustainable Development
  • 24. Side Effects Dapsone (DDS) Rifampicin (RFP) Clofazimine (CLF) Occasional cutaneous eruptions A slight reddish coloration of urine, sweat, and tears Brownish Black discoloration and dryness of skin
  • 25. Cases around the World A 20% annual decrease in new cases detected globally since 2001. the disease has been eliminated from 108 out of 122.
  • 26. A Day in the Patient’s Life AN AFFECTIONATE HAND FOR THE NEEDY………. http://i193.photobucket.com/albums/z96/whengzky/FR%20Joy%20pix/641c.jpg
  • 27. JALANETI: Technique related to yoga. It is the best remedy for nasal stiffness. Normal saline is passed through one nostril and is collected from other , which flushes the micro organisms.
  • 28. The disease was known in Ancient Greece as elephantiasis A common pre-modern treatment of leprosy was chaulmoogra oil. The oil has long been used in India as an Ayurvedic medicine for the treatment of leprosy and various skin conditions. It has also been used in China and Burma, and was introduced to the West by Frederic John , a professor at Bengal Medical CollegeBengal Medical College.  He tried the oil as an oral and topical agent in two cases of leprosy and reported significant improvements in an 1854 paper.
  • 29. REFERENCES:  Sasaki S, Takeshita F, Okuda K, Ishii N (2001). "Mycobacterium leprae and leprosy: a compendium" . Microbiol Immunol 45 (11): 729–36. PMID 11791665. http://www.jstage.jst.go.jp/article/mandi/45/11/729/_pdf. ^ a b c "New Leprosy Bacterium: Scientists Use Genetic Fingerprint To Nail 'Killing Organism'". ScienceDaily. 2008-11-28. http://www.sciencedaily.com/releases/2008/11/081124141047.htm. Retrieved 2010-01-31. ^ a b c Kenneth J. Ryan, C. George Ray, editors. (2004). Ryan KJ, Ray CG. ed. Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 451–3. ISBN 0838585299. OCLC 61405904 52358530 61405904. ^ a b "Lifting the stigma of leprosy: a new vaccine offers hope against an ancient disease". Time 119 (19): 87. May 1982. PMID 10255067. http://www.time.com/time/magazine/article/0,9171,925377,00.html. ^ Kulkarni GS (2008). Textbook of Orthopedics and Trauma (2 ed.). Jaypee Brothers Publishers. p. 779. ISBN 8184482426, 9788184482423. ^ "Q and A about leprosy". American Leprosy Missions. http://www.leprosy.org/getinformed/aboutleprosy/leprosyfaq.php. Retrieved 2011-01-22.17 - PRABHAKAR, M.C.; APPA RAO, A.V.N.; KRISHNA, D.R.; RAMANAKAR, T.V. How much noninfectious are the "non-infectious" lepromatous leprosy patients? Leprosy- India, 55(3): 576-583, 1983. ESSENTIALS OF MEDICAL PHARMACOLOGY BY K.D.TRIPATHI.